Objective To observe the effect of sling exercise therapy (SET) on rehabilitation after knee arthroplasty. Methods 46 patients after knee arthroplasty were randomly divided into experimental group (n=23) and control group (n=23). The control group received continuous passive motion (CPM) training, while the experimental group received SET. They were evaluated with range of motion (ROM) of the knee, Hospital for Special Surgery Knee Score (HSS) and posture control ability before, 15 days and 3 months after operation. Results 15 days after operation, the maximal passive knee flexion was 6.0° more in the SET group than in the CMP group (95%CI=0.9°~11.2°; P<0.01), and the maximal active knee flexion was 5.7° more in the SET group than in the CMP group (95%CI=0.4°~9.1°; P<0.01); however, there was no significant difference in the maximal active knee extension, the maximal passive knee extension, HSS and posture control ability between 2 groups (P>0.05). 3 months after operation, there was no significant difference in all the items between 2 groups (P>0.05). Conclusion Compared with CPM, SET might be more effective on increasing knee ROM in the short-term, and could be used as an effective intervention for patients after knee arthroplasty at the early stage.

Objective:To investigate the clinical efficacy of Omalizumab in the treatment of moderate-to-severe allergic asthma with allergic comorbidities in children.Methods:The clinical data of 50 children with moderate-to-severe allergic asthma and allergic comorbidities, who were treated with Omalizumab and completed 12-month follow-up in the Department of Pediatrics of Peking University First Hospital from July 2018 to March 2022, were retrospectively analyzed.A comparison was performed on the scale scores of childhood allergic asthma and allergic comorbidities including allergic rhinitis (AR) and chronic spontaneous urticaria (CSU), pulmonary function test indices and fractional exhaled nitric oxide (FeNO) concentration before and after treating with Omalizumab.The data were compared by ANOVA, paired t-test, chi- square test and rank sum test. Results:(1)Improvement of clinical symptoms: after 12 months of Omalizumab treatment, the childhood asthma control test score of 42 children aged ≤11 years increased from (20.98±5.03) points to (26.95±0.22) points ( F=18.189, P<0.001). The asthma control questionnaire 7 score of 50 children decreased from (0.89±0.11) points to (0.10±0.02) points ( F=5.662, P=0.006). The score of visual analogue scale of 47 children with AR decreased from (11.00±1.65) points to (0.2±0.14) points ( F=14.901, P<0.001), and the urticaria control test score of 13 children with CSU decreased from (4.82±0.88) points to (1.87±0.61) points ( F=4.329, P=0.018). (2)Improvement of quality of life: compared with those before treatment, the pediatric asthma quality of life questionnaire score in 50 children increased from (124.50±32.13) points to (159.40±6.21) points ( F=12.052, P<0.001), and global evaluation of asthma treatment effectiveness decreased from (2.23±0.70) points to (1.07±0.26) points ( F=68.865, P<0.001) after Omalizumab treatment for 12 months.(3)Improvement of pulmonary function results: after 12 months of Omalizumab treatment, the number of children with forced expiratory volume in one second/forced vital capacity< 80% decreased from 13 cases (26%) to 1 case (2%), and the values increased from (91.39±12.88)% to (96.96±8.54)%( χ2=11.960; t=2.486, all P<0.05). The peak expiratory flow of predicted value increased from (86.73±16.05)% to (94.01±13.11)% ( t=2.445, P<0.05). The number of children with two indicators among the forced expiratory flow at 50% of forced vital capacity exhaled, forced expiratory flow at 75% of forced vital capacity exhaled and maximal mid-expiratory flow lower than 65% decreased from 31 cases (62%) to 7 cases (14%) ( χ2=24.450, P<0.001). There was no significant difference in FeNO concentration before and after treatment ( P>0.05). Safety of Omalizumab: no obvious adverse reactions were found during treatment and follow-up. Conclusions:Omalizumab can significantly improve the clinical symptoms, small airway function and quality of life of children with allergic asthma and concomitant AR or CSU.It is a potential targeted drug for treating a variety of allergic diseases in children.

Objective:To explore the effect of conducting core stability training (CST) on an unstable supporting surface using thoracolumbar fracture patients with an incomplete spinal cord injury.Methods:Forty thoracolumbar fracture patients with incomplete spinal cord injury were randomly divided into an experiment group and a control group, each of twenty. Both groups received 30 minutes of CST five times per week for 8 weeks. The patients in the control group were trained on a stable supporting surface while those in the experiment group used an unstable surface. Evaluations were conducted before and after the 8-week intervention. Gait and static balance data were collected and analyzed using 3D motion analysis software and an EAB-100 active balancer.Results:After the intervention, the average stride length and comfortable walking speed of the experimental group were both significantly better than the control group′s averages. Moreover, the path length, circumferential area, rectangular area and effective value area of the Romberg rate were all significantly better, on average, in the experiment group, as was the average displacement of the deflection center with the eyes closed in static balance.Conclusions:An unstable supporting surface is superior to a stable one for conducting CST after thoracolumbar fracture with incomplete spinal cord injury. The effect may be due to improved nonvisual postural control.

Objective To compare the effects of intravenous thrombolysis with tenecteplase com-bined with endovascular treatment versus alteplase combined with endovascular treatment in patients with acute ischemic stroke(AIS).Methods A total of 98 patients with AIS in the hospital from Jan-uary 2021 to October 2022 were randomly divided into alteplase group and tenecteplase group,with 49 cases in each group.The alteplase group received alteplase thrombolysis combined with endovascular treatment,while the tenecteplase group received tenecteplase combined with endovascular treatment.General clinical materials were compared between the two groups;the National Institutes of Health Stroke Scale(NIHSS)scores at baseline(T0),1 hour after thrombolysis(T1),24 hours after endo-vascular treatment(T2),7 days after endovascular treatment(T3),and at discharge(T4)were com-pared between two groups;the modified Rankin Scale(mRS)scores and Barthel index(BI)scores at T0,30 days after endovascular treatment(T5),and 90 days after endovascular treatment(T6)were also compared between two groups;the length of hospital stay,occurrence of complications,and clini-cal efficacy were compared between the two groups.Results There were no significant differences in age,gender distribution,body mass index(BMI),hypertension,diabetes,coronary heart disease,smoking,alcoholism,cerebral infarction volume,infarction location,and clinical classification be-tween the two groups(P＞0.05).Compared with the alteplase group,the NIHSS scores at T,,T2,T3 and T4 were significantly lower in the tenecteplase group(P＜0.05).Similarly,the mRS scores at T5 and T6 were significantly lower while the BI scores at T5 and T6 were significantly higher in the tenecteplase group than the alteplase group(P＜0.05).The length of hospital stay was significantly shorter in the tenecteplase group than the alteplase group(P＜0.05).The incidence rates of post-treatment complications such as cerebral hemorrhage,gastrointestinal bleeding,skin and oral muco-sa bleeding,atrial fibrillation,and hypotension in the alteplase group were 10.20％,2.04％,8.16％,0％,and 8.16％respectively,while those in the tenecteplase group were 2.04％,4.08％,6.12％,2.04％,and 4.08％respectively;the incidence rate of cerebral hemorrhage in the tenecteplase group was significantly lower than the alteplase group(P＜0.05).The total effec-tive rate was 85.71％in the alteplase group,which was significantly lower than the 91.84％in the tenecteplase group(P＜0.05).Conclusion Compared with alteplase bridging therapy,tenecte-plase bridging therapy shows better clinical outcomes,which can improve the quality of life and prognosis of patients with AIS to a certain extent,reduce the probability of cerebral hemorrhage,and enhance clinical efficacy.

Objective To compare the effects of intravenous thrombolysis with tenecteplase com-bined with endovascular treatment versus alteplase combined with endovascular treatment in patients with acute ischemic stroke(AIS).Methods A total of 98 patients with AIS in the hospital from Jan-uary 2021 to October 2022 were randomly divided into alteplase group and tenecteplase group,with 49 cases in each group.The alteplase group received alteplase thrombolysis combined with endovascular treatment,while the tenecteplase group received tenecteplase combined with endovascular treatment.General clinical materials were compared between the two groups;the National Institutes of Health Stroke Scale(NIHSS)scores at baseline(T0),1 hour after thrombolysis(T1),24 hours after endo-vascular treatment(T2),7 days after endovascular treatment(T3),and at discharge(T4)were com-pared between two groups;the modified Rankin Scale(mRS)scores and Barthel index(BI)scores at T0,30 days after endovascular treatment(T5),and 90 days after endovascular treatment(T6)were also compared between two groups;the length of hospital stay,occurrence of complications,and clini-cal efficacy were compared between the two groups.Results There were no significant differences in age,gender distribution,body mass index(BMI),hypertension,diabetes,coronary heart disease,smoking,alcoholism,cerebral infarction volume,infarction location,and clinical classification be-tween the two groups(P＞0.05).Compared with the alteplase group,the NIHSS scores at T,,T2,T3 and T4 were significantly lower in the tenecteplase group(P＜0.05).Similarly,the mRS scores at T5 and T6 were significantly lower while the BI scores at T5 and T6 were significantly higher in the tenecteplase group than the alteplase group(P＜0.05).The length of hospital stay was significantly shorter in the tenecteplase group than the alteplase group(P＜0.05).The incidence rates of post-treatment complications such as cerebral hemorrhage,gastrointestinal bleeding,skin and oral muco-sa bleeding,atrial fibrillation,and hypotension in the alteplase group were 10.20％,2.04％,8.16％,0％,and 8.16％respectively,while those in the tenecteplase group were 2.04％,4.08％,6.12％,2.04％,and 4.08％respectively;the incidence rate of cerebral hemorrhage in the tenecteplase group was significantly lower than the alteplase group(P＜0.05).The total effec-tive rate was 85.71％in the alteplase group,which was significantly lower than the 91.84％in the tenecteplase group(P＜0.05).Conclusion Compared with alteplase bridging therapy,tenecte-plase bridging therapy shows better clinical outcomes,which can improve the quality of life and prognosis of patients with AIS to a certain extent,reduce the probability of cerebral hemorrhage,and enhance clinical efficacy.

Objective:To explore the clinical efficacy and safety of the new targeted anti-immunoglobulin E (IgE) drug Omalizumab in the treatment of children with moderate and severe allergic bronchial asthma in China.Methods:The clinical data of children with moderate and severe allergic asthma who were treated in the Department of Pediatrics of Peking University First Hospital from July 2018 to January 2020 and treated with Omalizumab were retrospectively analyzed.A comparison was performed on the changes of questionnaires, including childhood asthma control test (C-ACT), pediatric asthma quality of life questionnaire (PAQLQ), mini-asthma quality of life questionnaire (Mini-AQLQ) and global evaluation of asthma treatment effectiveness (GETE), pulmonary function test, including forced expiratory volume in the first second (FEV 1), percentage to predicted value (FEV 1% pred) and small airway function, fractional concentration of exhaled nitric oxide (FeNO) and so on, before and after treating with Omalizumab. Results:A total of 15 pediatric patients completed 16 weeks of treatment follow-up.After 16 weeks of Omazumab treatment, the score of C-ACT increased from (16.001.66) scores to (25.38±0.64) scores ( F=11.969, P<0.001), PAQLQ increased from (118.08 ± 23.78) scores to (141.00 ± 11.91) scores ( F=9.289, P=0.001), Mini-AQLQ increased from (78.93±7.43) scores to (97.92±3.12) scores ( F=4.145, P=0.042), and GETE decreased from (2.47±0.27) scores to (1.60±0.19) scores ( t=2.982, P=0.010). The actual value of FEV 1, FEV 1% pred, the maximum expiratory flow percentage of the predicted value (PEF% pred), forced expiratory flow at 25% (MEF 75), forced expiratory flow at 50% (MEF 50) and maximum midexpiratory flow (MMEF 75/25), increased from (1.96±0.12) L to (2.17±0.21) L ( F=0.425, P=0.789), (81.46±2.85)% to (82.64±1.55)% ( F=0.926, P=0.465), (82.05±3.58)% to (91.10±4.67)% ( F=1.909, P=0.128), (60.36±7.43)% to (76.94±4.65)% ( F=2.120, P=0.096), (52.72±3.75)% to (73.80±8.34)% ( F=3.140, P=0.047) and (60.05±8.47)% to (74.86±10.85)% ( F=7.860, P=0.010), respectively.FeNO decreased from 25.0 (14.5, 35.5) μg/L to 20.0 (18.5, 30.0) μg/L ( Z=-0.206, P=0.840). Transient headache was observed in 1 case and evanescent eruption in 2 cases during the treatment, respectively. Conclusions:Omalizumab can significantly improve the clinical manifestations, lung function indicators and quality of life of children with moderate and severe allergic asthma, and has good safety.Thus, it is expected to play an important role in the treatment of children with moderate-to-severe allergic asthma.